The Use of Alloderm Versus Dermacell in Immediate Implant Based Breast Reconstruction
- Conditions
- Breast Reconstruction
- Interventions
- Device: DermacellDevice: Alloderm
- Registration Number
- NCT03064893
- Lead Sponsor
- Ottawa Hospital Research Institute
- Brief Summary
Breast reconstruction after mastectomy has been shown to provide psychosocial benefits to breast cancer patients and is considered an integral part of breast cancer treatment. In general, breast reconstruction can be accomplished using the patients own tissues or implantable prosthetic devices. Various acellular dermal matrices (ADMs) are offered on the market and the costs vary widely despite very similar qualities. The two most commonly used ADM products in North America by far are Dermacell and Alloderm. The difference between the two products include a) level of sterility, with Dermacell being sterilized to 10-9 while Alloderm is sterilized to 10-6 and b) the consistency and thickness of the biologic material and c) a significant different in cost ($2200 CAD vs $3600, respectively). Each product has shown to be safe and effective. As such, clinical equipoise exists. This will be a pragmatic trial to evaluate Dermacell with Alloderm in a head to head randomized fashion, with regards to the postoperative complications, namely infection, seroma formation (as measured by drain duration and output), loss of implant, incidence of revisional surgery and capsular contracture.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 60
- Female patient
- Ages 20-90
- All patients undergoing mastectomy for breast cancer or prophylaxis for breast cancer with immediate implant-based reconstruction
- Able to provide verbal consent
- Patients who have had prior chest wall or irradiation on the reconstructed side
- Patients not undergoing immediate breast reconstruction at the time of mastectomy
- Any patient with a contraindication to immediate breast reconstruction
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Dermacell Dermacell Device for immediate implant based breast reconstruction Alloderm Alloderm Device for immediate implant based breast reconstruction
- Primary Outcome Measures
Name Time Method Postoperative duration of drain placements within 6 months of initial surgery
- Secondary Outcome Measures
Name Time Method Loss of implant within 6 months of initial surgery Revisional surgery/ return to operating room within 6 months of initial surgery Wound dehiscence or debridement within 6 months of initial surgery Episodes of seroma formation requiring aspiration within 6 months of initial surgery Number of additional postoperative clinic visits with the plastic surgeon (beyond the routine) within 6 months of initial surgery Economics of total costs 2 years Economic impact will be assessed based on calculation of total costs with each material used to include the material costs, duration of operative room use, clinic and inpatient hospital costs, surgical billing costs and anaesthesia costs
Capsular contracture (as identified by the plastic surgeon) within 6 months of initial surgery
Trial Locations
- Locations (1)
The Ottawa Hospital
🇨🇦Ottawa, Ontario, Canada